The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626001241325
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
30/06/2026
Date registered
Help: Date registered
13/10/2026
Date last updated
Help: Date last updated
13/10/2026
Date data sharing statement initially provided
Help: Data sharing statement date
13/10/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Phase 1a study to assess safety an tolerability of a single ascending dose of MMB-003 in Healthy Participants.
Scientific title
A Phase 1a Double Blind, Placebo-Controlled Single-Center Study to Evaluate
the Safety and Tolerability of Single Ascending Doses of MMB-003 in Healthy Participants.
Additional trial identifiers [1] 317644 0
Nil known
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Ulcerative Colitis 342421 0
Condition category
Condition code
Inflammatory and Immune System 338554 338554 0 0
Other inflammatory or immune system disorders
Oral and Gastrointestinal 338555 338555 0 0
Inflammatory bowel disease

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
MMB-003 is a recombinant live biotherapeutic product consisting of a genetically modified strain of Escherichia coli Nissle 1917, known as EcN::ttr. MMB-003 will be administered orally as a capsule containing micro encapsulated beads of live EcN::ttr.

Part 1 cohorts & dose levels which is a single dose once daily:
Cohort 1.1 - MMB-003 (1x10^6 CFU), 1 dose administered only on Day 1
Cohort 1.2 - MMB-003 (1x10^8 CFU), 1 dose administered only on Day 1
Cohort 1.3 - MMB-003 (1x10^10 CFU), 1 dose administered only on Day 1

This study consists of 2 parts and this registration is for:
Part 1 – SAD in 3 cohorts of healthy male and female participants, with a total of 12 healthy male and female participants enrolled.

There will be 3 cohorts of 4 participants. In each cohort, 3 will receive active, and 1 will receive placebo. In Part 1, sentinel dosing will be used (1:1:2) in each cohort. Participants will be randomized into the dose cohort and will not follow any specific order between the active and placebo treatment. The placebo could be assigned to any of the 4 participants in the cohort. The first participant will receive either MMB-003 or placebo as 1 dose daily on Day 0 (relative to that first participant’s dose), followed by a minimum 7-day gap to ensure adequate evaluation of safety and tolerability prior to administering the same dose of MMB-003 or placebo to the second sentinel participant, followed by dose administration of the same dose of MMB-003 or placebo for the remaining participants. A minimum 7-day gap between sentinels (first and second participants) will be applied, the third and fourth participants can be dosed on the same day. All participants will be observed at the clinic for a minimum of 2 hours after dosing, for safety and tolerability assessments, before discharge. Each dose cohort will be examined sequentially, with a minimum of 7 days of safety data from the last participant’s last dose in any cohort, to ensure adequate evaluation of safety and tolerability prior to administering the next dose level

Supervised dosing and medication review will occur at clinic visits.


Intervention code [1] 334474 0
Treatment: Drugs
Description of the comparator or control
MMB-003 capsules will be supplied at three dose levels along with matching placebo capsules containing microencapsulated beads made of non-active excipient ingredients (no bacteria).
Placebo (blank bead) 0 CFU/capsule
Supervised dosing and medication review will occur at clinic visits.


Control group
Placebo

Outcomes
Primary outcome [1] 345840 0
Part 1 (SAD) Healthy participants – To evaluate the safety of the novel microbiome therapeutic MMB-003 after single doses in healthy participants.
Timepoint [1] 345840 0
Safety lab tests collected Screening (Visit 1), Baseline Pre-Dose (Visit 2a), Dosing (Visit 2b), Virtual Follow-Up 24 hours post-dosing (Visit 3), Follow-Up Day 7 ±2 days (Visit 4), Virtual Follow-Up 14 days post-dosing (Visit 5), End of Study Day 28 ±4 days post-dosing (Visit 6)and unscheduled (as required).
Primary outcome [2] 345841 0
Part 1 (SAD) Healthy participants – To evaluate the tolerability of the novel microbiome therapeutic MMB-003 after single doses in healthy participants.
Timepoint [2] 345841 0
Adverse events will be collected Screening (Visit 1), Baseline Pre-Dose (Visit 2a), Dosing (Visit 2b), Virtual Follow-Up 24 hours post-dosing (Visit 3), Follow-Up Day 7 ±2 days (Visit 4), Virtual Follow-Up 14 days post-dosing (Visit 5), End of Study Day 28 ±4 days post-dosing (Visit 6)and unscheduled (as required).
Primary outcome [3] 347009 0
Part 1 (SAD) Healthy participants – To evaluate the safety of the novel microbiome therapeutic MMB-003 after single doses in healthy participants.
Timepoint [3] 347009 0
Vitals collected Screening (Visit 1), Baseline Pre-Dose (Visit 2a), Dosing (Visit 2b), Virtual Follow-Up 24 hours post-dosing (Visit 3), Follow-Up Day 7 ±2 days (Visit 4), Virtual Follow-Up 14 days post-dosing (Visit 5), End of Study Day 28 ±4 days post-dosing (Visit 6) and unscheduled (as required).
Secondary outcome [1] 463478 0
To characterize the pharmacokinetics (stool shedding) of MMB-003 in healthy participants.
Timepoint [1] 463478 0
Part 1 SAD (Healthy) participants Screening (Visit 1) – provided no later than 24 hours after Visit 1; Baseline Pre-Dose (Visit 2a) Day 0 – provided within 24 hours before receiving dose, Follow-Up (Visit 4) Day 7 ±2 days, and EOS (Visit 6) Day 28 ±4 days.
Secondary outcome [2] 463479 0
To assess individually the impact of MMB-003 on the gut microbiome composition (diversity) in stool samples collected from healthy participants.
Timepoint [2] 463479 0
Part 1 SAD (Healthy) participants Screening (Visit 1) – provided no later than 24 hours after Visit 1; Baseline Pre-Dose (Visit 2a) Day 0 – provided within 24 hours before receiving dose, Follow-Up (Visit 4) Day 7 ±2 days, and EOS (Visit 6) Day 28 ±4 days.
Secondary outcome [3] 463480 0
To assess the impact of MMB-003 on metabolites in plasma, urine, and stool collected from healthy participants.
Timepoint [3] 463480 0
Part 1 SAD (Healthy) participants Screening (Visit 1) – provided no later than 24 hours after Visit 1; Baseline Pre-Dose (Visit 2a) Day 0 – provided within 24 hours before receiving dose, Follow-Up (Visit 4) Day 7 ±2 days, and EOS (Visit 6) Day 28 ±4 days.
Secondary outcome [4] 463481 0
To assess the impact of MMB-003 on gene expression in peripheral blood from healthy participants.
Timepoint [4] 463481 0
Part 1: Screening (Visit 1) Follow Up (Visit 4) Day 7 ±2 days, and EOS (Visit 6) Day 28 ±4 days.
Secondary outcome [5] 463482 0
To assess the impact of MMB-003 on fecal calprotectin in healthy participants.
Timepoint [5] 463482 0
Part 1: Screening (Visit 1) – provided no later than 24 hours after Visit 1; Baseline Pre-dose (Visit 2a) Day 0 – provided within 24 hours before receiving dose, Follow-Up (Visit 4) Day 7 ±2 days, and EOS (Visit 6) Day 28 ±4 days.
Secondary outcome [6] 468111 0
To assess individually the impact of MMB-003 on the function in metagenomics in stool samples collected from healthy participants.
Timepoint [6] 468111 0
Part 1 SAD (Healthy) participants Screening (Visit 1) – provided no later than 24 hours after Visit 1; Baseline Pre-Dose (Visit 2a) Day 0 – provided within 24 hours before receiving dose, Follow-Up (Visit 4) Day 7 ±2 days, and EOS (Visit 6) Day 28 ±4 days.

Eligibility
Key inclusion criteria
1. In the opinion of the Investigator, the participant is capable of understanding and complying with protocol requirements.
2. The participant signs and dates an informed consent form.
3. Male or female participants aged 18-65 years.
4. Body Mass Index (BMI) between 18.0 and 30.0 kg/m2.
5. Good general health as determined by medical history, physical examination, and routine laboratory tests. No clinically significant abnormalities that, in the opinion of the investigator, may increase the risk or interfere with study assessments.
6. Willingness and ability to provide informed consent and comply with study procedures and assessments.
7. Agree to avoid any major changes from the participant’s typical dietary practices (e.g. start a new diet such as vegan, vegetarian, carnivore, etc.) for the duration of the study.
8. Females either of non-childbearing potential or using a contraceptive (e.g. hormonal pill, IUD) during study and for 60 days following administration of investigational drug.
9. All participants must agree to use a double physical barrier (e.g. male condom and a diaphragm) and abstain from unprotected anal sex and/or analingus for 60 days following each administration of the investigational drug (per OGTR DIR 221 Licence Condition 28). This is to prevent any potential transmission of the GMO to a non-participant.


Minimum age
18 Years
Maximum age
65 Years
Sex
Both males and females
Healthy volunteers
Yes
Key exclusion criteria
1. Past or present clinically significant gastrointestinal disease including chronic constipation, chronic diarrhea, Crohn's disease, UC, celiac disease, irritable bowel syndrome, or parasitic infection within 3 months of screening.
2. Use of antibiotics within 1 month prior to screening.
3. Use of probiotics/prebiotics within 2 weeks prior to screening. Consumption of food products such as yogurt, kefir, kombucha and herbal teas is permissible.
4. Use of agents that can alter gut transit time (e.g., laxatives, anti-diarrheal medications, and diabetic and weight loss medications)
5. Recipient of Fecal Microbial Transplantation (FMT) or other fecal derived therapy, within 6 months prior to screening.
6. Any acute or chronic medical condition that, in the opinion of the Investigator, would make participation unsafe.
7. Pregnancy or lactation.
8. History of taking an investigational therapy within 60 days of first dose of study drug.
9. Positive screening test for human immunodeficiency virus (HIV) or hepatitis panel.
10. Addiction to alcohol or illicit drugs (cannabis-derived products less than 3 times a week excepted whether illicit or not) within the last year.
11. Positive urine drug screen at Screening, other than for cannabis-derived products consistent with the permitted use describe above, unless another positive result is attributable to a documented permitted medication and is considered not clinically significant by the Investigator.
12. Participant does not have a mobile device (Android or iOS).


Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
The randomization schedule linking kit codes to treatment assignment (active vs. placebo) will be accessible only to designated overseas Melius employees who are not otherwise involved in study conduct and who labels the product. All study team members at the clinical site will remain blind to treatment assignment for the duration of the study.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
The randomization will be generated by the Integrated Medical Development portal.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

Intervention assignment
Parallel
Other design features
Phase
Phase 1
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis
The sample size chosen of 4 participants in each cohort (3 active: 1 placebo) is considered to be sufficient for evaluation of safety and tolerability of each cohort. The sample size was not based on statistical power considerations.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD
Recruitment hospital [1] 30279 0
Mater Misericordiae Ltd – QLD - South Brisbane Qld 4101
Recruitment postcode(s) [1] 46682 0
4101 - South Brisbane Qld 4101

Funding & Sponsors
Funding source category [1] 322184 0
Commercial sector/Industry
Name [1] 322184 0
Melius MicroBiomics Pty Ltd
Country [1] 322184 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
Melius MicroBiomics Pty Ltd
Address
Country
Australia
Secondary sponsor category [1] 325093 0
None
Name [1] 325093 0
Address [1] 325093 0
Country [1] 325093 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320713 0
Bellberry Human Research Ethics Committee D
Ethics committee address [1] 320713 0
Ethics committee country [1] 320713 0
Australia
Date submitted for ethics approval [1] 320713 0
24/06/2026
Approval date [1] 320713 0
08/09/2026
Ethics approval number [1] 320713 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 151378 0
A/Prof Jakob Begun
Address 151378 0
Mater Hospital Brisbane, Mater Misericordiae Ltd Raymond Terrace South Brisbane QLD 4101
Country 151378 0
Australia
Phone 151378 0
+61 731632371
Fax 151378 0
Email 151378 0
Contact person for public queries
Name 151379 0
Sharyn Grossman
Address 151379 0
Mater Hospital Brisbane, Mater Misericordiae Ltd Raymond Terrace South Brisbane QLD 4101
Country 151379 0
Australia
Phone 151379 0
+61 73163 8195
Fax 151379 0
Email 151379 0
Contact person for scientific queries
Name 151380 0
Jakob Begun
Address 151380 0
Mater Hospital Brisbane, Mater Misericordiae Ltd Raymond Terrace South Brisbane QLD 4101
Country 151380 0
Australia
Phone 151380 0
+61 73163 2371
Fax 151380 0
Email 151380 0

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Regulatory authorities: Information obtained during the research study is subject to inspection for the purpose of verifying the study procedures and data by the relevant authorities (such as the TGA in Australia or the United States of America Food and Drug Administration), authorised representatives of the Sponsor such as study monitors acting on behalf of the Sponsor and its affiliates, representatives, partners, or collaborators, and vendors utilised by the Sponsor for study conduct, the Human Research Ethics Committee (HREC) that reviewed and approved this study, the Institution at which this study is being conducted, or as required by law.

Contract Research Organisation (CRO): Study monitors (people working for or on behalf of the trial Sponsor) to visit the clinical unit to review the clinical trial data so they can verify that study procedures have been followed and the study data have been entered correctly in the study records. This process is called ‘data verification’. This process typically takes place during regular monitoring visits to the Mater Misericordiae Ltd. Monitors are only allowed to view the information for data verification and are not allowed to share your data with other parties. Your medical files are reviewed at the clinical unit for the purposes of the study, your records will be kept secure during this process.

Sponsor/Mater Misericordiae Ltd will share certain information from this study so that others can use it and understand the study findings. This study information does not identify the participant individually.


Conditions for requesting access:
• Yes, conditions apply:
• Requires review on a case-by-case basis by the trial custodian, sponsor or data sharing committee
What individual participant data might be shared?
• All de-identified individual participant data
What types of analyses could be done with individual participant data?
• Any type of analysis (i.e. no restrictions on data re-use)
When can requests for individual participant data be made (start and end dates)?
From:
At the end of the study
To:
No end date
Where can requests to access individual participant data be made, or data be obtained directly?
• Request to be made to Mater Misericordiae Ltd who hold the participant medical records.
Sharyn Grossman +61 7 3163 8195


Are there extra considerations when requesting access to individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.